Q3 2023 Results
October 26, 2023

Forward Looking Statements and Non-GAAP Financial Information

This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results
and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements thatare not statements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by, these statements asa result of various factors, including, but not limited to, (i) new laws and regulations, (ii) our ability to obtain, protect and maintain market exclusivity rights and enforce patents and otherintellectual property rights, (iii) our ability to achieve expected clinical, regulatory and contractual milestones on expected timelines or at all, (iv) difficulties or delays in the development andcommercialization of new products, (v) difficulties or delays in our clinical trials and the manufacturing, distribution and sale of our products, (vi) adverse outcomes in legal or regulatory
proceedings, (vii) risks relating to acquisitions, divestitures, alliances, joint ventures and other portfolio actions, including our ability to complete the acquisition of Mirati Therapeutics, Inc. and(viii) political and financial instability, including changes in general economic conditions. These and other important factors are discussed in the Company’s most recent annual report on Form
10-K and reports on Forms 10-Q and 8-K. These documents are available on the U.S. Securities and Exchange Commission’s website, on the Company’s website or from Bristol-Myers Squibb
Investor Relations. No forward-looking statements can be guaranteed.
In addition, any forward-looking statements and clinical data included herein are presented only as of the date hereof. Except as otherwise required by applicable law, the Company undertakes
no obligation to publicly update any of the provided information, whether as a result of new information, future events, changed circumstances or otherwise.
This presentation includes certain non-generally accepted accounting principles (“GAAP”) financial measures that we use to describe the Company’s performance. The non-GAAP financial
measures are provided as supplemental information and are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or
the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the Company’s baseline performance, supplement
or enhance management’s, analysts’ and investors’ overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past andfuture periods. This presentation also provides certain revenues and expenses excluding the impact of foreign exchange (“Ex-FX”). We calculate foreign exchange impacts by converting ourcurrent-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-FX financial measures are
not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.
The non-GAAP information presented herein provides investors with additional useful information but should not be considered in isolation or as substitutes for the related GAAP measures.
Moreover, other companies may define non-GAAP measures differently, which limits the usefulness of these measures for comparisons with such other companies. We encourage investors toreview our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. An explanation of these non-GAAP financial measures and areconciliation to the most directly comparable financial measure are available on our website at www.bms.com/investors.
Also note that a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating margin, non-GAAP operating expenses and non-GAAP tax rate is not provided because acomparable GAAP measure for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for suchreconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of the unwind of inventory purchase price adjustments, accelerated depreciation andimpairment of property, plant and equipment and intangible assets, and stock compensation resulting from acquisition-related equity awards, or currency exchange rates. In addition, theCompany believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may havea material impact on our future GAAP results.
Q3 2023 Results

Not for Product Promotional Use2

Q3 2023 Results

Giovanni Caforio, MD
Board Chair and Chief Executive Officer3

Q3 2023 Results

Chris Boerner, PhD
Chief Operating Officer

Chief Executive Officer, effective November 1, 2023

4

Q3 2023 PerformanceCommercial& Financial
Execution

Business
Development

Q3 Global Net Sales

Medium-Term Financial Targets*• 11.0B; (2%) YoY; (3%) Ex-FX*

Reaffirms1:

In-Line Brands & New Product Portfolio• ~$9.3B; +8% YoY; +7% Ex-FX*

Financial
Outlook•••

Low-to-mid single digit revenue CAGR2
Low double-digit revenue CAGR2 ex-Rev/Pom$8–10B revenue growth from in-line brands3

Earnings per Share (EPS)

Adjusts:• GAAP $0.93, +24% YoY• Non-GAAP* $2.00, +1% YoY••Entered into acquisition agreementwith planned close by 1H 2024•

Strengthens & diversifies Oncology
portfolio

Q3 2023 Results•

Pipeline
Execution>$10B growth from new product portfolio in
2026
Operating margin to >37%4•

Reblozyl: U.S. approval in 1L MDS
associated anemia (COMMANDS)•

Opdivo: U.S. & EU approval in Stage II
adj. melanoma (CM-67K); positive Ph3 in
SC nivolumab (CM-67T) & peri-adj. lung
(CM-77T)•

LPA1 antagonist: Established PoC in PPF*See “Forward-Looking Statements and Non-GAAP Financial Information” and “Bristol Myers Squibb Company Reconciliation of Certain GAAPLine Items to Certain Non-GAAP Line Items”
1. 2020-2025 Financial Targets 2. At constant exchange rates on a risk-adjusted basis 3. Primarily I-O & Eliquis 4. Target through 2025

Not for Product Promotional Use

5Our Goal is to Deliver Sustainable Growth
Four Key Enablers

Evolve R&D for
scientific leadership

Strong commercial
execution to realize
value of ourmarketed portfolio

Execute strategic
capital allocation tofurther strengthen
our growth profile

Foster a highperformance culture
and attract & retain
industry-leading talent

We are driven by our mission: Transforming patients’ lives through scienceQ3 2023 Results

Not for Product Promotional Use

6

Solid Momentum in Q3 & Accelerating Future Growth
New Product Portfolio

Key In-Line Products

Outlook*$ in millions$928+67% ex-FX*

$43
$66
$68

• Strong U.S. demand
growth offset by grossto-net adjustments

$92

$553

$21
$5

$123
$166

Q3 2022

Reblozyl
Camzyos

Opdualag
Sotyktu• Planned expansion of
new product portfoliowith repotrectinib1 &Krazati2

$248

$190

Zeposia
Onureg*See “Forward-Looking Statements and Non-GAAP Financial Information”**Q3 2022 sales: Camzyos - $5M & Sotyktu - $1M

Q3 2023

AbecmaInrebic

1.
2.

• Expect >$10B revenue
from new productportfolio in 2026
• Focused on productacceleration to enable
future growth

$93

$69
$84

• Continued demand
growthQ3 2023 Results

**

$32
$44
$107

$1

• Delivered key clinicalmilestones to enable
future growth$29

Breyanzi

U.S. PDUFA: November 27, 2023
Subject to satisfaction of customary closing conditions;anticipated closing by 1H 2024

Not for Product Promotional Use

7

Strong Delivery from our R&D Engine Since R&D Day
Oncology

Immunology

Hematology

Opdivo‒ U.S. approval in Stage II
adj. melanoma

LPA1 antagonist‒ Breakthrough Therapy
Designation granted in PPF

Reblozyl‒ U.S. approval in 1L MDS
associated anemia with abroad label

CD19 NEX T Cell Therapy‒ Enrolling patients in Ph1severe, refractory SLE
trial

Other assets‒ Data to be presented on
key assets at ASH 2023

‒ Peri-adj. lung & 1L MIUC
presented at ESMO‒ Met co-primary endpoints
for SC nivolumab1
Krazati2‒ 1L lung TPS ≥ 50%
encouraging Ph2 data at
ESMO‒ Achieved FDA clearance toinitiate MS trial

1. Subcutaneous nivolumab could provide U.S. approval in indications representing 65-75% of Opdivo business & benefit patients into the early 2030s
Not for Product Promotional Use
Q3 2023 Results 2.
Subject to satisfaction of customary closing conditions; anticipated closing by 1H 2024

8

Mirati Therapeutics: Strong Strategic Fit• Best-in-class KRASG12C inhibitor approved in 2L+ mutated NSCLC;
confirmatory Ph3 results expected 1H 2024

Extending in IO• Potential KRASG12C mutated tumor opportunities: 1L NSCLC; 2L & 3L+ CRC
Indication
1L NSCLC
2L CRC
3L+ CRC

Diversifying beyond IO
repotrectinib1(U.S. PDUFA: 11/27/23)

Development

StatusTPS ≥ 50%: Krazati + pembrolizumab

Ph3 initiation by YE 2023

TPS < 50%: Krazati + pembrolizumab + chemo

Ph2 data expected in 1H 2024

Krazati + cetuximab

Ph3 data expected in 2024
Ph2 submission expected by YE 2023

Selective PRMT5/MTA inhibitor (MRTX1719): Potential first-in-class asset•

Ph2 expected to initiate 1H 2024; Fast Track Designation granted

2

Early Clinical Programs: Additional opportunities from KRAS inhibitors &enabling programs (e.g., SOS1 inhibitor)

Planned close by 1H 20242
Q3 2023 Results

1. Acquired from Turning Point Therapeutics
2. Subject to satisfaction of customary closing conditions; anticipated closing by 1H 2024

Not for Product Promotional Use

9

Continued Strong Pipeline Execution
2023 Key Milestones
Early Stage:

Opdivo(+/- Yervoy)

 Neo-adjuvant NSCLC Ph3(CM-816) approval in EU

iberdomide

Metastatic:

 1L mCRPC Ph3 (CM-7DX)
Opdualag 1L NSCLC Ph21

repotrectinib

 ROS1+ NSCLC (TRIDENT-1)
U.S. filing

AbecmaBreyanzi 3-5L MM Ph3 (KarMMa-3)
filing
 Initiation NDMM Ph3(KarMMa-9)
 2L TE LBCL EU approval
 3L+ CLL Ph1/2(TRANSCEND-CLL)
 3L+ FL Ph2 (TRANSCENDFL)

Q3 2023 Results

2024/2025 Key Milestones
Metastatic:

 Initiation of pivotal
post-transplantmaintenance H2H vs
Revlimid

Reblozyl

 1L MDS (COMMANDS)
U.S. filing

Sotyktu Mod-to-severe PsO
EU approval CD Ph2 (IM011-023)
 UC Ph2 (IM011-127)

LPA1
Antagonist

 Initiation IPF Ph3
 PPF Ph2 (IM027-040)

Camzyos oHCM EU approval

LIBREXIA(milvexian) Initiation Ph3
program2

1. Data readout anticipated early 2024
2. ACS, SSP, AF trials conducted by Janssen

Opdivo(+/- Yervoy)

 1L HCC Ph3 (CM-9DW)
 1L+ MSI High CRC Ph3(CM-8HW)

Reblozyl

 1L MF Ph3(INDEPENDENCE)

cendakimab EoE Ph3

Early Stage:

Sotyktu PsA Ph3

 Peri-adj NSCLC Ph3
Zeposia(CM-77T) Peri-adj MIBC Ph3(CM-078)
 Adj HCC Ph3 (CM-9DX)
 Stage III Unresectable
NSCLC Ph3 (CM-73L)
 Adj NSCLC Ph3(ANVIL, co-op group)

Opdualag 1L HCC Ph2
 2L+ HCC Ph2
 2L/3L+ MSS mCRC Ph3

alnuctamab
BCMA TCE Initiation MM Ph3

Milestones represent data readouts unless otherwise specified;subject to positive registrational trials and health authority approval CD maintenance Ph3(YELLOWSTONE)

Not for Product Promotional Use

10Numerous Levers to Drive Long-Term Growth
Extended durability of our IO business with subcutaneous nivolumab and Opdualag
Increasingly de-risked the New Product Portfolio
Number of registrational assets increasing from 6 to 12 over the next 18 months
Developing medicines in rapidly growing markets with significant commercial opportunities
Leading positions with differentiated platforms in Cell Therapy and Targeted Protein Degradation
Strategic optionality from Business Development

Q3 2023 Results

Not for Product Promotional Use

11

Q3 2023 Results

David Elkins

Executive Vice President
and Chief Financial Officer

12

Total Company Performance Driven by In-Line & New Product
Portfolios
Total Company Sales ~$11B(2%) YoY, (3%) Ex-FX*

$2.6

$8.6

Q3 2022
Recent LOEs

$B

Q3 Net Sales1

YoY %Ex-FX* %

$11.0

(2%)

(3%)

In-Line Products

$8.3

+3%

+3%

New Product
Portfolio

$0.9

+68%

+67%

In-Line Products &New Product Portfolio

$9.3

+8%

+7%

Recent LOEs2

$1.7

(35%)

(35%)

Total Company

$1.7

$9.3

Q3 2023
In-Line & New Products

Q3 2023 Results

1.
2.

Amounts may not add due to rounding
Recent LOE Brands = Revlimid & Abraxane*See “Forward-Looking Statements and Non-GAAP Financial Information”

Not for Product Promotional Use

13

New Product Portfolio Performance
Building strong momentum for future growth$ in millions+67% growth vs PY Ex-FX*$ in millions$928$2,513

$43
$66
$68
$92

**

$553
$1,385

$1

$32
$44

$29

$93

$21
$5

$123

$107
$166

$69
$84

$730

$248

$190
YTD 2021

YTD 2022

Q3 2023 Results

YTD 2023*See “Forward-Looking Statements and Non-GAAP Financial Information”**Q3 2022 sales: Camzyos - $5M & Sotyktu - $1M

Q3 2022
Reblozyl
Camzyos

Opdualag
Sotyktu

Q3 2023
Zeposia
OnuregAbecmaInrebic

Breyanzi

Not for Product Promotional Use

14

Q3 2023 Oncology Product Summary
Q3 Global Net Sales
Opdivo:$M

YoY %Ex-FX* %• U.S. YoY volume growth in 1L lung, upper GI & adj.
bladder cancer$2,275+11%+11%• Ex-U.S. YoY growth of +15% ex-FX* primarily fromdemand in 1L lung & upper GI & expanded access

$579

+11%

+10%

$166

+98%

+98%

$260

+47%

+51%

Q3 2023 Results

Opdualag:• U.S. growth driven by strong demand; ~25% market
share1 in 1L melanoma• A new SOC in 1L melanoma

1. Source: BMS Internal Analysis*See “Forward-Looking Statements and Non-GAAP Financial Information”

Not for Product Promotional Use

15

Q3 2023 Cardiovascular Product Summary
Q3 Global Net Sales
$M

YoY %

Ex-FX* %

$M

YoY %

Ex-FX* %$2,705

+2%

-

$68

**

**

First-in-class myosin inhibitor

Best-in-class & leading OAC within category
Eliquis:• U.S. growth driven by strong underlying
demand offset by gross-to-net adjustments• U.S. increase in total treated & commercial
dispensed patients• Expansion in international markets based on
reimbursement timing• Ex-U.S. impacted by generic entry in UK &Canada, and pricing measures
Patients in hub
Patients on commercial drug

Q3 2023 Results

1. Source: BMS Internal Analysis*See “Forward-Looking Statements and Non-GAAP Financial Information”**In excess of +100%

As of June 30, 20231

As of Sept 30, 20231

~3800
~2500

~4900
~3500

Not for Product Promotional Use

16

Q3 2023 Hematology Product Summary
Q3 Global Net Sales1
1Revlimid: FY 2023 revenue projection ~$6.0B

$M

YoY %

Ex-FX* %Reblozyl:$1,429

(41%)

(41%)

• U.S. FDA approval in August 2023 in 1L MDS-associatedanemia with a broad label (COMMANDS)

$872

(2%)

(2%)

$517

(8%)

(8%)

• U.S. strong YoY growth of +28% driven by demand fromincreased 1L use & 2L switches from ESAs as well as DoT

$248

+31%

+29%

$93

(13%)

(14%)

$92

**

**

$43

+34%

+31%

$29

+38%

+33%

Q3 2023 Results

1. Empliciti grouped in Mature & Other Brands

Abecma:• Q3 impacted by manufacturing maintenance in June &increased availability of additional BCMA targeting agents
Breyanzi:• Continued strong demand in 2L/3L+ LBCL
• Q3 impacted by timing of infusions*See “Forward-Looking Statements and Non-GAAP Financial Information”**In excess of +100%

Not for Product Promotional Use

17

Q3 2023 Immunology Product Summary
Q3 Global Net Sales
%

$M

YoY %

Ex-FX* %

$925

+5%

+5%

$123

+78%

+75%

%

$M

YoY %

Ex-FX* %

$66

**

**

First-in-class selective allosteric TYK2 inhibitor• U.S. continued volume growth; ~$30M clinical purchase inquarter

Zeposia:• Growth from demand in MS & expanding
contribution from UC• Continued focus on improving formulary access• Expansion in international markets based on
reimbursement timing

Q3 2023 Results

1. Source: BMS Internal Analysis; 2. Cumulative TRx
equivalent since launch; 3. Market share of written oralprescriptions in NBRx sourced from BrandImpact• Progress converting patients on CVS indication-based plans• Driving demand to enable broader access in 2024 & 2025
Cumulative Volume2
Market Share3
Source of Business4• Systemic-naïve
• Biologic-experienced• Otezla-experienced

As of June 30, 20231>23K TRx Equivalent35-40%

As of Sept 30, 20231>38K TRx Equivalent
~40%

>40%
>30%
>25%

>40%
>30%
>25%

4. Q3 Source of Business proportionally distributes 15% unknown/unidentified*See “Forward-Looking Statements and Non-GAAP Financial Information”;**In excess of +100%

Not for Product Promotional Use18

Q3 2023 Financial Performance
US GAAPGAAPUS$ in billions, except EPS

Non-GAAP *Non-GAAP

Q3 2023

Q3 2022

Q3 2023

Q3 2022

Total Revenues, net

11.0

11.2

11.0

11.2

Gross Margin %

77.1%

79.0%

77.3%

79.8%

Operating Expenses1

4.2

4.3

4.1

4.1

Acquired IPR&D

0.1

-

0.1

-

Amortization of Acquired Intangibles

2.3

2.4

-

-

Effective Tax Rate

9.5%

27.2%

11.6%

16.9%

Diluted EPS

0.93

0.75

2.00

1.99

Diluted Shares Outstanding (# in millions)

2,064

2,148

2,064

2,148

Diluted EPS Impact from Acquired IPR&D2(0.03)

0.02(0.03)

0.02

Q3 2023 Results

1. Operating Expenses = MS&A and R&D
2. Comprises the net impact from Acquired IPRD & Licensing income*See “Forward-Looking Statements and Non-GAAP Financial Information”

Not for Product Promotional Use

19

Balanced Approach to Capital Allocation
Cash flow from Operations $B$4.8
Business
Development

$3.7
$3.3

• Prioritize opportunities to further diversify
portfolio & strengthen long-term outlook‒ Entered into agreement to acquire Mirati
Therapeutics; planned close by 1H 2024

$3.0
$1.9
Balance Sheet
Strength

Q3
2022

Q4
2022

Q1
2023

Q2
2023

$B

Q3 2023

Total Cash*~$8.0B

Total Debt~$37.6B• Maintain strong investment-grade credit rating

Q3
2023

Returning Cashto Shareholders• Continued annual dividend growth**• Opportunistic share repurchase‒ Executed $4B ASR Agreements in Q3’23‒ Approx. $2B remaining share authorization

Strong operating cash flow generation
Q3 2023 Results*Cash includes cash, cash equivalents and marketable debt securities**Subject to Board approval
Note: YTD operating cash may not add due to rounding

Not for Product Promotional Use

20

Revised 2023 Guidance
US GAAP*

Non-GAAP*

July (Prior)

October (Revised)

July (Prior)

October (Revised)

Total Revenues
Reported Rates

Low-single digit decline

No Change

Low-single digit decline

No Change

Total Revenues
Ex-FX

Low-single digit decline

No Change

Low-single digit decline

No Change

Revlimid~$5.5 billion~$6.0 billion~$5.5 billion~$6.0 billion

Gross Margin %~76%

No Change~76%

No Change

Low-single digit decline

No Change

Low-single digit decline

No Change

Tax Rate

~16%

~11%

~17.5%~15.5%

Diluted EPS$3.72 - $4.02$3.68 - $3.83$7.35 - $7.65$7.50 - $7.65

Operating Expenses1

Q3 2023 Results

1. Operating Expenses = MS&A and R&D, excluding Acquired IPR&D and Amortization of acquired intangibles*See “Forward-Looking Statements and Non-GAAP Financial Information”

Not for Product Promotional Use

21

Medium-Term Guidance*
July 2023

October 2023

• Low-to-mid single-digit revenue CAGR1 from2020-2025• Reaffirms low-to-mid single-digit revenue CAGR1
from 2020-2025• Low double-digit revenue CAGR1 ex-Rev/Pomfrom 2020-2025• Reaffirms low double-digit revenue CAGR1 exRev/Pom from 2020-2025• $8B-$10B growth from in-line brands2 from2020-2025• Reaffirms $8B-$10B growth from in-line brands2
from 2020-2025• $10B-$13B from New Product Portfolio in 2025

• Adjusts to >$10B revenue from new productportfolio in 2026

• 40%+ operating margin through 2025

• Adjusts operating margin target to >37% through2025

Q3 2023 Results*See “Forward-Looking Statements and Non-GAAP Financial Information” and “Bristol Myers Squibb Company Reconciliation of Certain GAAPLine Items to Certain Non-GAAP Line Items”
1. At constant exchange rates on a risk-adjusted basis 2. Primarily I-O & Eliquis

Not for Product Promotional Use

22

Q3 2023 Results Q&A

Giovanni Caforio, MD
Board Chair,Chief Executive Officer

Chris Boerner, PhD

Executive VP,
Chief Operating Officer,
CEO effective November 1, 2023

David Elkins

Executive VP,
Chief Financial Officer

Samit Hirawat, MD

Executive VP,
Chief Medical Officer,
Global Drug Development

Adam Lenkowsky

Executive VP,
Chief Commercialization Officer

23

Bristol Myers Squibb Company Reconciliation of Certain
GAAP Line Items to Certain Non-GAAP Line Items(Unaudited, dollars in millions)Year-Ended December 31
2020

2021

2022

Total Revenues$42,518$46,385$46,159

Gross Profit$30,745$36,445$36,022

Specified items (a)$3,300$603$356

Gross Profit excluding specified items$34,045$37,048$36,378

Marketing, Selling and Administrative$7,661$7,690$7,814

Specified items (a)($279)

($3)

($79)

Marketing, Selling and Administrative excluding
specified items$7,382$7,687$7,735

Research and Development$10,048$10,195$9,509Specified items (a)($903)($843)($308)

Research and Development excluding specified
items$9,145$9,352$9,201

Operating margin

31%

40%

41%

Specified items (a)

10%

3%

1%

Operating margin excluding specified items (b)

41%

43%

42%

Q3 2023 Results(a): An explanation of these non-GAAP financial measures and a reconciliation to the most directly comparable GAAP
financial measure are available on our website at bms.com/investors.
(b): Operating margin on Specified Items represents the difference between the GAAP and Non-GAAP operating margin

Not for Product Promotional Use

24

2023 Key News Flow
TimingAsset

TimingOpdivoEU approval in Neo-Adj. Lung EFS(CM-816)EU Approval June 2023

Reblozyl
EU approval in NTD Beta-Thalassemia
Associated Anemia

EU Approval March 2023

Opdivo
1L mCRPC Ph3 (CM -7DX)

Study Discontinued1

Reblozyl
1L TD MDS Associated Anemia(COMMANDS) filing

Asset

OpdualagStage IV 1L NSCLC Ph2 (CA227-104)
repotrectinib
ROS1+ NSCLC (TRIDENT-1) filing
Abecma3-5L MM (KarMMa-3) filing

Presented at ASCO & EHA 2023
U.S. approval August 2023 &filed in EU & Japan

1H 2024

Sotyktu
EU approval in mod-to-severe PsO
POETYK PSO-1 & PSO-2

EU Approval March 2023

Priority Review: U.S. PDUFA
November 27, 2023

Sotyktu
Crohn’s Disease Ph2 (LATTICE-CD)

PoC not achieved

U.S. PDUFA December 16, 2023;
filed in EU & Japan

Sotyktu
Ulcerative Colitis (higher dose) Ph2(IM011-127)

PoC not achieved

EU approval May 2023

LPA1 Antagonist
Progressive Pulmonary Fibrosis (PPF) Ph2(IM027-040)

Achieved PoC

Breyanzi
3L+ CLL Ph1/2 (TRANSCEND-CLL)

Met primary endpoint
in January 2023
Presented at ASCO 2023

Camzyos
EU approval in symptomatic obstructive
HCM (EXPLORER-HCM)

EU Approval June 2023

Breyanzi
2L & 3L+ FL Ph2 (TRANSCEND-FL)

Positive topline resultsin April 2023
Presented at ICML 2023

Camzyos
U.S. & EU approval in obstructive HCM
SRT eligible (VALOR)

U.S. & EU approval June 2023

Breyanzi
EU approval in 2L LBCL (Transplant
Eligible)

Q3 2023 Results

1Did not meet primary endpoints of rPFS at FA nor OS at IA

Milestones represent data readouts or approvals unless otherwise
specified; subject to positive registrational trials and health authority
approval

Not for Product Promotional Use

25

Q3 2023 Opdivo Sales Mix
U.S. Sales Mix

11%

Ex-U.S. Sales Mix

24%

21%

29%

24%
7%

21%
20%

Q3 2023 Results

18%
25%

Note: percentages are approximate

Not for Product Promotional Use

26

Q3 2023 Eliquis NBRx/TRx Share

NBRx Share – US

TRx Share - US

24%

21%

10%

9%

67%

70%

Q3 2022

Q3 2023

EliquisQ3 2023 Results

Warfarin

25%

23%

15%

13%

60%

64%

Q3 2022

Q3 2023

Other NOACs

Rx Source: IQVIA

Not for Product Promotional Use

27

Our ESG updates and looking ahead
ESG Materiality Assessment Results

2022 ESG Report Completed a global, double ESG materiality assessment1 and identified the
8 ESG factors that were rated as most “material” by stakeholders

 On August 23, 2023, published BMS’ 2022 ESG
Report,2 providing increased transparency anddisclosures

 Results showed strong alignment of internal and external stakeholders’priorities
TOP 8 Material ESG Factors
1. Pricing & Patient Access2. Product Innovation
3. Patient Safety and Product Quality
4. Ethics & Conduct
5. Long-Term Value Creation
6. Culture and Inclusion & Diversity
7. Climate Change & Emissions
8. Public Health & Public Policy

Breakdown:
Top ESG
Issues by
Theme

Business
Model &
Innovation,
26%

SocialCapital,36%

2022 Highlights Include: 58% clinical trial sites in diverse metro areas

Leadership &Governance,16%

 $1B global spend on diverse-owned businesses

Human
Capital,11%
Environment,11%

 8.2% reduction in greenhouse gas emissions acrossScopes 1, 2, & 3 compared to 2021

Looking Ahead
Evolved ESG Strategy based on double
materiality assessment will be sharedin 2024
Q3 2023 Results

Task Force on Climate-Related Financial
Disclosures (TCFD) report will be
published later this year
1 BMS ESG Materiality Assessment
2 BMS 2022 ESG Report

Science-based emissions reduction targets
anticipated to be validated by the Science
Based Targets Initiative (SBTi) by 2024

$150 million to address
health disparities will be
provided by end of 2025
Not for Product Promotional Use

28

Clinical Development Portfolio – Phase I and II
Phase II

Phase I
 AHR Antagonist*^ Anti-CCR8^
 Anti-ILT4^
 AR LDD DGK Inhibitor
 Helios CELMoD JNK Inhibitor
 MAGE A4/8 TCER*
 NME 1 SHP2 Inhibitor^
 TGFβ Inhibitor^
 TIGIT Bispecific alnuctamab
 Anti-SIRPα BCL6 LDD
 BCMA NKE
 BET Inhibitor (BMS-986378)^
 CD33 NKE
 CK1α Degrader
golcadomide^ GPRC5D CAR T FXIa Inhibitor
 Anti-CD40
 CD19 NEX T
 IL2-CD25
 NME 2 PKCθ Inhibitor
 Anti-MTBR-Tau
 BTK Inhibitor
 eIF2b Activator FAAH/MGLL Dual Inhibitor

Q3 2023Oncology
Results

Solid Tumors
Solid Tumors
Solid Tumors
1L, 2L Metastatic Castration-Resistant Prostate
CancerSolid Tumors
Solid Tumors
Solid Tumors
Solid Tumors
Prostate Cancer
Solid Tumors
Solid Tumors
Solid Tumors
Lung Cancer
Gastric Cancer
RR Multiple Myeloma
Hematologic Malignancies
Lymphoma
RR Multiple Myeloma
RR Non-Hodgkin’s Lymphoma
Acute Myeloid Leukemia
Hematologic Malignancies
1L Diffuse Large B-cell Lymphoma
RR Multiple Myeloma
Thrombotic Disorders
Autoimmune Disease
Severe Refractory Systemic Lupus
Erythematosus
Autoimmune Disease
Autoimmune Disease
Autoimmune Disease
Alzheimer’s Disease
Neuroscience
Neuroscience
Neuroscience

Hematology

Data as of October 26th, 2023

CV

Neuroscience Anti-CTLA-4 NF Probody® Therapeutic Anti-Fucosyl GM1^
 Anti-IL-8^
 Anti-NKG2A^
 BET Inhibitor (BMS-986378)^
 farletuzumab ecteribulin
nivolumab+relatlimab
 repotrectinib
 BET Inhibitor (BMS-986158)

Solid Tumors
Lung Cancer
Colorectal Cancer
RR Small Cell Lung Cancer
Solid Tumors
Non-Small Cell Lung Cancer
Solid Tumors
Ovarian Cancer
Non-Small Cell Lung Cancer
Stage IV 1L Non-Small Cell Lung Cancer
1L Hepatocellular Carcinoma
NTRK Pan-Tumor
1L Myelofibrosis
3L+ Chronic Lymphocytic Leukemia (CLL)RR Follicular Lymphoma (FL)RR Marginal Zone Lymphoma (MZL)RR Mantle Cell Lymphoma (MCL)RR Non-Hodgkin’s Lymphoma
Myelodysplastic Syndrome
A-Thalassemia

BREYANZI

 golcadomide
ONUREGREBLOZYL

 danicamtiv

Heart Failure with preserved Ejection Fraction(HFpEF)
Dilated Cardiomyopathy

 MYK-224

Obstructive Hypertrophic Cardiomyopathy afimetoran

Systemic Lupus Erythematosus

CAMZYOS

Alopecia Areata

SOTYKTU

Discoid Lupus Erythematosus

 TYK2 Inhibitor (BMS-986322)

Immunology* Partner-run study

Moderate-to-Severe Psoriasis

NME leading indication^ Trials exploring various combinations


Not for Product Promotional Use

29

Clinical Development Portfolio – Phase III
Phase IIIOPDIVOOPDIVO + YERVOYOPDUALAG
 SC nivolumab + relatlimab + rHuPH20
 SC nivolumab + rHuPH20 (multi-indications) ABECMA
iberdomide
mezigdomide
REBLOZYLCAMZYOS milvexian cendakimab
LPA1 Antagonist
 obexelimab * #SOTYKTUZEPOSIA

Q3 2023 Results

Adjuvant Hepatocellular Carcinoma
Peri-adjuvant Muscle-Invasive Urothelial Carcinoma
Peri-adjuvant Non-Small Cell Lung Cancer
Stage IB-IIIA Adjuvant NSCLC*
1L Hepatocellular Carcinoma
1L Muscle Invasive Urothelial Carcinoma
1L+ Microsatellite Instability High Colorectal Cancer
Stage 3 Unresectable Non-Small Cell Lung Cancer
Adjuvant Melanoma
2L/3L+ Metastatic Colorectal Cancer
1L Melanoma
2L Renal Cell Carcinoma
Newly Diagnosed Multiple Myeloma with Suboptimal
Response post-ASCT2L+ Multiple Myeloma
Post-Autologous Stem Cell Therapy Maintenance Newly
Diagnosed Multiple Myeloma2L+ Multiple Myeloma Vd
2L+ Multiple Myeloma Kd
1L TD Myelofibrosis Associated Anemia
1L NTD Myelodysplastic Syndrome Associated Anemia
Non-Obstructive Hypertrophic Cardiomyopathy
Secondary Stroke Prevention*
Acute Coronary Syndrome*
Atrial Fibrillation*
Eosinophilic Esophagitis
Eosinophilic Gastroenteritis #Idiopathic Pulmonary Fibrosis (IPF)
Progressive Pulmonary Fibrosis (PPF)
IgG4-Related Disease
Psoriatic Arthritis
Systemic Lupus Erythematosus
Sjögren's Syndrome
Crohn’s Disease

Data as of October 26th, 2023

Registration US, EU, JP
repotrectinib

ROS1 NSCLC (US, JP)

ABECMA

3-5L Multiple Myeloma (US, EU, JP)

REBLOZYL

1L TD Myelodysplastic Syndrome Associated Anemia (EU, JP)

Oncology

Hematology

CV

Neuroscience

Immunology* Partner-run study NME leading indication# Certain Asian territories

Development Partnerships:

ABECMA: 2seventy bio; AHR: Ikena Oncology; Anti-MTBR-Tau: Prothena;
CAMZYOS in China, Singapore, Thailand, Macau, HK, Taiwan: LianBio;
farletuzumab ecteribulin: Eisai; rHuPH20: Halozyme; MAGEA4/8 TCER:
Immatics; milvexian: Janssen Pharmaceuticals, Inc.; OPDIVO, YERVOY,OPDUALAG in Japan: Ono; PKCθ Inhibitor: Exscientia; REBLOZYL: Merck; SHP2
Inhibitor: BridgeBio Pharma; TIGIT Bispecific: Agenus; obexelimab: Zenas
BioPharma in Japan, South Korea, Taiwan, HK, Singapore, and Australia
Not for Product Promotional Use30

Q3 2023 Late-Stage Drug Development Clinical Trials Update
Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Opdivoiberdomide

Breyanzi

cendakimab

milvexian

Opdualagmezigdomide

Abecma

LPA1 antagonist

Camzyos

repotrectinib

Reblozyl

Sotyktu

OnuregZeposia

alnuctamab

obexelimab

Q3 2023 Results

Not for Product Promotional Use

31

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Opdivo (anti-PD1)
Lung Cancer Trials
Indication

Peri-Adjuvant NSCLC

Phase/Study

Phase III – CheckMate -77T

# of Patients

N = 452

Design• Neoadjuvant Opdivo 360mg + PDCT Q3W for
4 cycles followed by adjuvant Opdivo
480mg Q4W for 1 year
• Neoadjuvant placebo + PDCT followed byplacebo• Opdivo Q4W• Observation (patients followed
serially with imaging for 1 year)• Opdivo + CCRT followed by Opdivo + Yervoy• Opdivo + CCRT followed by Opdivo• CCRT followed by durvalumab• Primary: EFS• Key secondary: OS• Primary: DFS, OS• Primary: PFS• Key secondary: OS

Status• Positive topline results in September 2023
• Data presented at ESMO 2023 as a Late
Breaker in the Presidential Symposium• Projected data readout 2025

• Projected data readout 2024

CT Identifier

NCT04025879

Endpoints

Q3 2023 Results

Stage IB-IIIA Adjuvant NSCLC

Stage III Unresectable NSCLC

Phase III – ANVIL

Phase III - CheckMate -73L

N = 903N = 888

Non-BMS Sponsored*

NCT02595944*Trial conducted by NCI/ECOG

NCT04026412

Not for Product Promotional Use

32

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Opdivo (anti-PD1)
Early-Stage Trials
Indication

Peri-Adjuvant MIUC

Adjuvant HCC

Phase/Study

Phase III - CA 017-078

Phase III – CheckMate -9DX

# of Patients

N = 861

N = 545

DesignEndpoints• Opdivo 360 mg Q3W for four cycles + chemotherapy• Chemotherapy• Opdivo 480 mg Q4W• Placebo• Primary: pCR, EFS• Key secondary: OS• Primary: RFS• Key secondary: OS• Projected data readout 2025

• Projected data readout 2025

StatusCT Identifier

NCT03661320

Q3 2023 Results

NCT03383458

Not for Product Promotional Use

33

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Opdivo (anti-PD1)
Metastatic Trials
Indication

1L HCC

1L+ MSI High CRC

Phase/Study

Phase III – CheckMate -9DW

Phase III - CheckMate -8HW

# of Patients

N = 732

N = 831

Design• Opdivo + Yervoy• sorafenib/lenvatinib• Opdivo (Arm A)• Opdivo + Yervoy (Arm B)• Chemotherapy (Arm C)• Primary: OS• Key secondary: ORR

Primary:• PFS Arm B vs. A, all lines• PFS Arm B vs. C, first line

Endpoints• Key secondary: ORR, OS

Status• Projected data readout 2025

CT Identifier

NCT04039607

Q3 2023 Results• Projected data readout 2025
NCT04008030

Not for Product Promotional Use

34

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Opdivo (anti-PD1)
Metastatic Trials
Indication

1L MIUC

2L RCC SC

Phase/Study

Phase III - CheckMate -901

Phase III - CheckMate -67T

# of Patients

N = 1,290

N = 454

Design• PD-L1+ & cis-ineligible: Opdivo 1 mg/kg + Yervoy 3 mg/kg Q3W up to
4 cycles followed by Opdivo 480 mg Q4W vs SOC chemotherapy• Cis-eligible: Opdivo 360 mg in combination with chemotherapy Q3W
vs SOC chemotherapy• Opdivo + rHuPH20 SC• Opdivo IV

Primary:• PFS, OS in cis-eligible patients• OS in PD-L1+ (>=1%) & cis-ineligible

Primary:• Cavgd28 (Opdivo serum concentration)• Cminss

Endpoints• Key secondary: ORR

Status• Positive topline results in cis-eligible in July 2023
• Data presented at ESMO 2023 as a Late Breaker in the Presidential
Symposium• Cis-eligible data published in NEJM October 2023
• Projected data readout 2024 in cis-ineligible• Did not meet primary OS endpoint in PD-L1+

CT Identifier

NCT03036098

Q3 2023 Results• Positive topline results in October 2023

NCT04810078

Not for Product Promotional Use

35

Oncology

Hematology

Cell Therapy

Immunology

CardiovascularOpdualag (anti-LAG3 + anti-PD1 FDC)
Indication

Adjuvant Melanoma

1L Melanoma SC

2L/3L+ MSS mCRC

Phase/Study

Phase III – RELATIVITY-098

Phase III – RELATIVITY-127

Phase III - RELATIVITY-123# of Patients

N = 1050

N = 814

N = 700

Design• Relatlimab + nivolumab FDC 160
mg/480 mg Q4W• Nivolumab 480mg Q4W• Relatlimab + nivolumab + rHuPH20 FDC SC• Relatlimab + nivolumab FDC IV• Relatlimab + nivolumab FDC• Investigator's Choice: regorafenib or TAS-102(trifluridine/tipiracil)• Primary: RFS• Key secondary: OS

Primary:• Cavgd28 of nivolumab; Cminss of nivolumab• Cavgd28 of relatlimab; Cminss of relatlimab

Primary :• OS in PD-L1 CPS≥1• OS in all-comers• Key secondary: ORR• Key secondary: ORR• Recruiting• Projected data readout 2025

• Projected data readout 2025

NCT05625399

NCT05328908

Endpoints• Projected data readout 2026

StatusCT Identifier

NCT05002569

Q3 2023 Results

Not for Product Promotional Use

36

Oncology

Hematology

Cell Therapy

Immunology

CardiovascularOpdualag (anti-LAG3 + anti-PD1 FDC)
Indication

1L HCC

1L Stage IV NSCLC

Phase/Study

Phase I/II - RELATIVITY-106

Phase II - CA224-104# of Patients

N = 162

N = 420• Nivolumab + relatlimab + bevacizumab• Nivolumab + placebo + bevacizumab

DesignPart II:• Nivolumab + relatlimab Dose 2 + PDCT
• Nivolumab + PDCT
Primary: DLTs, ORR

Primary:• Part I: TRAEs leading to discontinuation within 12 weeks after firstdose• Part II: ORR• Recruiting• Projected data readout 2024

• Projected data readout 2024

Endpoints

StatusPart I:• Nivolumab + relatlimab Dose 1 + PDCT
• Nivolumab + relatlimab Dose 2 + PDCTCT Identifier

NCT05337137

Q3 2023 Results

NCT04623775

Not for Product Promotional Use

37

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularrepotrectinib (ROS1/NTRK)Indication

ROS1 NSCLC & NTRK+ Solid Tumors

Phase/Study

Phase I/II – TRIDENT-1# of Patients

N = 500
Phase I:
• Dose escalation; food-effect, dose escalation with food; & Midazolam DDI

DesignEndpoints

Phase II: Expansion cohorts• ROS1 TKI-naïve ROS1+ NSCLC 160 mg QD for the first 14 days, then 160 mg BIDa
• 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC• 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or I-O)
• 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or I-O)
• TRK TKI-naïve NTRK+ solid tumors• TRK TKI-pretreated NTRK+ solid tumors
Primary:• Phase I: DLTs, RP2D
• Phase II: ORR
Key Secondary• Phase II: DOR, IC-ORR

Status• Recruiting• U.S. FDA Priority Review in ROS1+ NSCLC: PDUFA November 27, 2023
• ROS1 data presented at IASLC WCLC 2023

CT Identifier

NCT03093116
Q3 2023 Results

aBased on tolerability

Not for Product Promotional Use

38

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularmezigdomide (CELMoD)
Indication

2L+ MM

2L+ MM

Phase/Study

Phase III – SUCCESSOR-1

Phase III – SUCCESSOR-2# of Patients

N = 810N = 575• Mezigdomide 0.3, 0.6, 1.0 mg + bortezomib 1.3 mg/m2a +dex 20 mg - (MeziVd)• Pomalyst 4 mg + bortezomib 1.3 mg/m2a + dex 20 mg - (PVd)• Mezigdomide 0.3, 0.6, 1.0 mg + carfilzomib 56 mg/m2b + dex 40 mg b
- (MeziKd)• Carfilzomib 56 mg/m2a + dex 20 mga - (Kd)

• Primary: PFS• Key secondary: OS• Primary: PFS• Key secondary: OS• Recruiting• Projected data readout 2026

• Recruiting• Projected data readout 2026

DesignEndpoints

StatusCT Identifier

NCT05519085

Q3 2023 Results

NCT05552976

a BIW dosing; b QW dosing

Not for Product Promotional Use

39

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

iberdomide (CELMoD)
Indication

2L+ MM

Post-Transplant Maintenance NDMM

Phase/Study

Phase III – EXCALIBER

Phase III – EXCALIBER-Maintenance# of Patients

N = 864

N = 1,216

Design• Iberdomide 1.0, 1.3,1.6 mg + daratumumab 1800 mg + dex 40
mg - (iberDd)• Daratumumab 1800 mg + bortezomib 1.3 mg/m2a + dex 20 mga (DVd)• Iberdomide Dose 0.75, 1.0, 1.3 mg• Lenalidomide 10 mg• Primary: PFS• Key secondary: OS• Primary: PFS• Key Secondary: MRD, OS• Recruiting• Projected data readout 2026

• Recruiting• Projected data readout 2029

Endpoints
StatusCT Identifier

NCT04975997

Q3 2023 Results

NCT05827016

aBIW dosing

Not for Product Promotional Use

40

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Reblozyl (Erythroid Maturation Agent)
Indication

1L Myelodysplastic Syndrome (MDS)
Associated Anemia

1L TD Myelofibrosis (MF)
Associated Anemia

Phase/Study

Phase III - COMMANDS

Phase III - INDEPENDENCE# of Patients

N = 362

N = 309

Design• Reblozyl 1.0 mg/kg SC Q3W• Epoetin Alfa 450 IU/kg SC QW• Reblozyl 1.33 mg/kg SC Q3W + JAK2i• Placebo SC Q3W + JAK2i• Primary: RBC-TI for 12 weeks with a mean hemoglobin
increase ≥ 1.5 g/dL through week 24• Primary: RBC-TI during any consecutive 12-week period starting
within the first 24 weeks

Endpoints

Status• Key secondary: RBC-TI ≥ 16 weeks (RBC-TI 16)• U.S. FDA approval August 2023
• Application under review in EU & Japan• Data presented at ASCO & EHA 2023

CT Identifier

NCT03682536

Q3 2023 Results• Recruiting• Expected data readout 2025

NCT04717414

Not for Product Promotional Use

41

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Reblozyl (Erythroid Maturation Agent)
Indication

TD & NTD Alpha-Thalassemia(Ex-US study)

1L NTD Low-or Intermediate Risk
Myelodysplastic Syndrome (MDS) Associated Anemia

Phase/Study

Phase II - CA056-015

Phase III – ELEMENT-MDS# of Patients

N = 177

N = 360

DesignEndpoints

Status• Reblozyl 1.0 mg/kg SC Q3W• Placebo SC Q3W + Best Supportive Care

• Reblozyl 1.0 mg/kg SC Q3W• Epoetin Alfa 450 IU/kg SC QWPrimary:• TD: ≥50% reduction in TF burden over any rolling 12
weeks between W13-W48• NTD: ≥1 g/dL Hb mean increase from baseline in W13W24
Key secondary:• TD: No. of participants with ≥ 33% reduction frombaseline in RBC transfusion burden• NTD: Change from baseline to W24 in hemoglobin in theabsence of transfusion

Primary:• Proportion of participants during Wk 1-96 who convert to TD (≥ 3units/16 weeks per IWG 2018)
Key secondary:• Mean hemoglobin increase ≥ 1.5 g/dL + TI for at least
16 wks during Wk 1-48

• Recruiting• Expected data readout 2025

• Recruiting• Expected data readout 2027

CT Identifier

NCT05664737

Q3 2023 Results

NCT05949684

Not for Product Promotional Use

42Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Onureg (Hypomethylating Agent)
Indication(IPSS-R) Low-or Intermediate Risk MDS

Phase/Study

Phase II/III – METEOROID# of Patients

N = 230
Part I:• Onureg 200 mg, 300 mg in Phase II + Best Supportive Care

DesignEndpoints

Part II:• Onureg RP3D in Phase III + Best Supportive Care
• PlaceboPrimary:• Safety & Tolerability & RP3D (Phase II)• Achieved Complete Remission per IWG 2006 within 6 cycles (Phase II & III)Key Secondary:• 84-day pRBC TI (Phase II & III)

Status• Recruiting• Projected data readout 2026

CT Identifier

NCT05469737

Q3 2023 Results

Not for Product Promotional Use

43Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularalnuctamab (BCMA x CD3 T-Cell Engager)
Indication

4L+ MM

Phase/Study

Phase I - CC-93269-MM-001# of Patients

N = 220

DesignEndpoints

Status• alnuctamab 10, 30, 60 mg SC
Primary:• RP2D• Safety and tolerability• Data presented at ASH 2022
• Projected data readout 2027

CT Identifier

NCT03486067

Q3 2023 Results

Not for Product Promotional Use

44Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Breyanzi (anti-CD 19 CAR T)
Indication

R/R NHL

R/R iNHL

3L+ CLL

Phase/Study

Phase I/II – TRANSCEND

Phase II – TRANSCEND FL

Phase II – TRANSCEND CLL# of Patients

N = 385

N = 213N = 209

DesignEndpoints

StatusCT Identifier• Breyanzi• Breyanzi

Study included R/R DLBCL, MCL, FL 3B, & PMBCLiNHL includes 3L+ FL, 2L FL (high risk), 3L+ MZL• Breyanzi• Breyanzi + ibrutinib• Breyanzi + venetoclax• Primary: ORR• Primary: ORR• Primary: CRR• Positive topline results in R/R MCL in April
2023• Data presented as Late Breaker at ICML
2023 in R/R MCL• Positive topline results in R/R FL in April
2023• Data presented as Late Breaker at ICML
2023 in R/R FL• Projected data readout 2025 in 3L+ MZL• Met primary endpoint in monotherapy arm
in January 2023
• Data presented at ASCO 2023

NCT02631044

NCT04245839

NCT03331198

Q3 2023 Results

Not for Product Promotional Use

45Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Abecma (anti-BCMA CAR T)
Indication

3L-5L MMNDMM with Suboptimal Response post-ASCT

Phase/Study

Phase III – KarMMa-3

Phase III – KarMMa-9# of Patients

N = 381

N = 618• Abecma• Standard regimens as per Investigator's discretion– DPd, DVd, IRd, Kd, EPd• Abecma followed by lenalidomide maintenance• Lenalidomide maintenance therapy alone• Primary: PFS• Key secondary: OS• Primary: PFS• Key secondary: OS

•
•
•
•

• Recruiting• Projected data readout 2027

DesignEndpoints

StatusU.S. PDUFA December 16, 2023
Application under review in EU & Japan
Data presented at EHA EBMT 2023
Published in NEJM February 2023

CT Identifier

NCT03651128

Q3 2023 Results

NCT06045806

Not for Product Promotional Use

46Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularcendakimab (anti-IL-13)
Indication

Eosinophilic Esophagitis (EoE)

Eosinophilic Gastroenteritis (EGE)(Japan study)

Phase/Study

Phase III - CC-93538-EE-001

Phase III - CC-93538-EG-001# of Patients

N = 399

N = 45

DesignEndpoints
Status• Cendakimab 360 mg SC QW for 24 weeks, followed by 360 mg SC• Cendakimab for 48 weeks• Placebo for 48 weeks

Primary:• Change in Dysphagia Days (clinical response) at week 24• Eosinophil histologic response (≤ 6/hpf) at week 24• Primary: Eosinophil histologic response (change from baseline) at• Expected data readout 2024

• Expected data readout 2024

QW for 24 weeks• Cendakimab 360 mg SC QW for 24 weeks, followed by 360 mg SC
Q2W for 24 weeks• Placebo for 48 weeks

CT Identifier

NCT04753697

Q3 2023 Results

week 16• Key secondary: clinical response up to week 48

NCT05214768

Not for Product Promotional Use

47

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

LPA1 antagonist
Indication

Idiopathic Pulmonary Fibrosis

Progressive Pulmonary Fibrosis

Phase/Study

Phase III – IM027-068

Phase III – IM027-1015# of Patients

N = 1,185

N = 1,092

DesignEndpoints

Status• LPA1 Dose 60 mg BID• LPA1 Dose 120 mg BID• Placebo• LPA1 Dose 60 mg BID• LPA1 Dose 120 mg BID• Placebo• Primary: Absolute change from baseline in forced vital capacity• Primary: Absolute change from baseline in forced vital capacity• Recruiting• Expected data readout 2026

• Recruiting• Expected data readout 2028

(FVC) measured in ML• Key secondary: Disease progression

CT Identifier

NCT06003426

Q3 2023 Results(FVC) measured in ML• Key secondary: Disease progression

NCT06025578

Not for Product Promotional Use48

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Sotyktu (TYK-2 inhibitor)
Psoriatic Arthritis (PsA)

Indication
Phase/Study

Phase III - POETYK-PsA-1

Phase III - POETYK-PsA-2# of Patients

N = 650

N = 700

DesignEndpoints
Status52-week study of patients with active PsA in TNF-naïve patients• Sotyktu 6 mg QD• Placebo

52-week study of patients with active PsA in TNF-naïve and TNF-IR
patients• Sotyktu 6 mg QD• Placebo• Apremilast• Primary: % pts achieving ACR20 response at Week 16• Primary: % pts achieving ACR20 response at Week 16• Recruiting• Expected data readout 2025 (52 wks)

• Expected data readout 2024 (52 wks)

NCT04908202

NCT04908189

CT IdentifierQ3 2023 Results

Not for Product Promotional Use

49

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Sotyktu (TYK-2 inhibitor)
Indication

Systemic Lupus Erythematosus (SLE)

Discoid Lupus Erythematosus (DLE)

Sjogren's (SjS)

Phase/Study

Phase III - POETYK SLE-1

Phase III - POETYK SLE-2

Phase II - IM011-132

Phase III - POETYK SjS-1# of Patients

N = 490

N = 490

N = 75

N = 756• Sotyktu 3 mg BID• Placebo• Sotyktu 3 mg BID• Placebo

52-week study:• Sotyktu Dose 1• Sotyktu Dose 2• Placebo• Sotyktu 3 mg BID• Sotyktu 6 mg BID• Placebo• Primary: Proportion of• Primary: Proportion of• Primary: Change from baseline in• Primary: Change from

Status• Recruiting• Expected data readout 2026

• Recruiting• Expected data readout 2026

• Recruiting• Expected data readout 2025

• Recruiting• Expected data readout

CT Identifier

NCT05617677

NCT05620407

DesignEndpoints

participants who meet
response criteria SRI-4 atweek 52

Q3 2023 Results

participants who meet
response criteria SRI-4 atweek 52

CLASI-A activity score at week 16

NCT04857034

baseline in ESSDAI atweek 52

2027

NCT05946941

Not for Product Promotional Use

50

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Sotyktu (TYK-2 inhibitor)
Indication

Alopecia Areata (AA)Phase/Study

Phase II – IM011-134# of Patients

N = 90DesignEndpoints
Status• Sotyktu Dose 1• Sotyktu Dose 2• Placebo, followed by Sotyktu Dose 1 or Dose 2• Primary: Change from baseline in SALT score at Week 24• Expected data readout 2024

CT Identifier

NCT05556265

Q3 2023 Results

Not for Product Promotional Use

51

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Zeposia (S1P agonist)
YELLOWSTONE Program: Crohn’s Disease (CD) - Moderate to Severe

Indication
Phase/Study

Phase III - RPC01-3201(Induction 1)

Phase III - RPC01-3202(Induction 2)

Phase III - RPC01-3203(Maintenance)# of Patients

N = 600

N = 606

N = 485

Design• Zeposia 0.92 mg QD• Placebo• Zeposia 0.92 mg QD• Placebo• Zeposia 0.92 mg QD• Placebo• Primary: Proportion of pts in clinicalremission (CDAI* score < 150) at week 12• Primary: Proportion of pts in clinicalremission (CDAI* score < 150) at week 12

Primary:• Proportion of pts in clinical remission(CDAI score of < 150) at week 52• Proportion of pts with a Simple
Endoscopic Score for Crohn's Disease(SES-CD) decrease of ≥ 50% at week 52

•

•

•

Endpoints

Expected data readout 2025

Expected data readout 2024

StatusCT Identifier

NCT03440372

Q3 2023 Results

NCT03440385

Expected data readout 2026 (52 wks
post induction & basis for filing)

NCT03464097

Not for Product Promotional Use

52

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularobexelimab (CD19 x FcγRIIB bifunctional mAb)
IgG4-Related Disease(ex-US study)

Indication
Phase/Study

Phase III – INDIGO# of Patients

N = 200

DesignEndpoints
StatusNon-BMS Sponsored*• Obexelimab SC• Placebo SC• Primary: Time to first IgG4-RD flare that requires initiation of rescue therapy in the opinion of the investigator and the Adjudication
Committee (AC) from randomization to Week 52• Recruiting• Expected data readout 2025

CT Identifier

NCT05662241

Q3 2023 Results*Trial conducted by Zenas BioPharma

Not for Product Promotional Use

53

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascularmilvexian (FXIa inhibitor)
Indication
Phase/Study

Secondary Stroke Prevention

Acute Coronary Syndrome

Phase III – LIBREXIA-STROKE

Phase III – LIBREXIA-ACS

Phase III – LIBREXIA-AF

Non-BMS Sponsored*

Non-BMS Sponsored*

Non-BMS Sponsored*

N = 15,000

N = 16,000

N = 15,500# of Patients
Design• Milvexian 25 mg BID + background• Milvexian 25 mg BID + background

antiplatelet therapy• Placebo + background antiplatelet
therapy

antiplatelet therapy• Placebo + background antiplatelet therapy

Status• Primary: Time to first occurrence of• Primary: Time to first occurrence of MACE

Key secondary:• Time to first occurrence of any
component of the composite of CVD, MI,or ischemic stroke• Time to first occurrence of ischemic
strokeKey secondary:• Time to first occurrence of any componentof the composite of MAVE• Recruiting• Projected data readout 2026 (event• Recruiting• Projected data readout 2026 (event

CT Identifier

driven)driven)NCT05702034
Q3 2023 Results• Milvexian 100 mg BID• Eliquis

Note: participants enrolled within 7 days of ACS +/catheterizationischemic stroke

Endpoints

Non-Valvular Atrial Fibrillation

NCT05754957*Trials conducted by Janssen• Primary: Time to first occurrence ofcomposite endpoint of stroke & non-CNS
system embolism

Key secondary:• Time to first occurrence of ISTH major
bleeding• Time to first occurrence of the composite
of ISTH major & CRNM bleeding• Recruiting• Projected data readout 2027 (event
driven)NCT05757869
Not for Product Promotional Use

54

Oncology

Hematology

Cell Therapy

Immunology

Cardiovascular

Camzyos (myosin inhibitor)
Indication

Heart Failure with Preserved Ejection Fraction (HFpEF)

Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

Phase/Study

Phase II - EMBARK

Phase III - ODYSSEY-HCM# of Patients

N = 35

N = 420

DesignEndpoints

Status• Camzyos• Camzyos• PlaceboPrimary:• TEAEs and SAEs
• Effect on NT-proBNP levels• Effect on cTnT levels (at rest)

Primary:• Change from baseline in Clinical Summary Score (KCCQ-23 CSS)at Week 48• Change from baseline in peak oxygen consumption (pVO2) at
Week 48
Secondary: Change from baseline in VE/VCO2 slope to Week 48• Projected data readout 2024

• Recruiting• Projected data readout 2025

CT Identifier

NCT04766892

Q3 2023 Results

NCT05582395

Not for Product Promotional Use

55Abbreviations
AA

Alopecia Areata

EoE

Eosinophilic Esophagitis

MTD

Maximum Tolerated Dose

RP3D

Recommended Phase 3 DoseAACR

American Association for Cancer
Research

ESA

Erythropoietin Stimulating Agents

MZL

Marginal Zone Lymphoma

ROS

C-ROS Oncogene

Adj

Adjuvant

ESCC

Esophageal Squamous Cell Carcinoma

nHCM

AE

Adverse Event

FDC

Fixed Dose Combination

ND

Non-Obstructive Hypertrophic Cardiomyopathy RR
SAE
Newly Diagnosed

AHA

American Heart Association

FDA

Food & Drug Administration

Subcutaneous

Acute Myeloid Leukemia

FL

Follicular Lymphoma

NSCLC Non-Small Cell Lung Cancer
NTD
Non-Transfusion Dependent

SC

AML

SCT

Stem Cell Transplant

ASH

American Society of Hematology

Hb

Hemoglobin

NTRK

SLE

Systemic Lupus Erythematosus

HCC
Hepatocellular Carcinoma
HFpEF Heart Failure w/ Preserved Ejection Fraction
iNHL
Indolent Non-Hodgkin's Lymphoma

BCMA

B-Cell Maturation Antigen

BID

Twice a Day

BIW

Twice a Week

CAR T

Chimeric Antigen Receptor Therapy I-O
Immuno-Oncology
Concurrent Chemoradiation Therapy IPSS-R International Prognostic Scoring System
IV
Crohn’s Disease
Intravenous

CCRT
CD

Neurotrophic Tyrosine Receptor Kinase

Relapsed Refractory
Serious Adverse EventNYHA

New York Health Association

SoC

Standard of CareoHCM

Obstructive Hypertrophic CardiomyopathysPGA

Static Physicians Global Assessment

ORR

Overall Response Rate

SRI

Systemic Lupus Responder Index

OS

Overall Survival

SRT

Septal Reduction Therapy

PASI

Psoriasis Area and Severity Index

SSP

Secondary Stroke PreventionpCR

Pathological Complete Response

SubQ/SC Subcutaneous

CDAI

Crohn's Disease Activity Index

LBCL

Large B-Cell Lymphoma

PDCT

Platinum-Based Chemotherapy

TDTransfusion Dependent

CLL

Chronic Lymphocytic Leukemia

LVOT

Left Ventricular Outflow Tract

PDL

Programmed Death Ligand

TE

Transplant Eligible

CM

Checkmate

mCRPC Metastatic Castration-Resistant Prostate Cancer

TEAE

Treatment Emergent Adverse EventsCR

Complete Response

MDS

Myelodysplastic Syndrome

PDUFA Prescription Drug User Fee ActPF
Pulmonary Fibrosis

TKI

Tyrone Kinase Inhibitor

CRR

Complete Remission Rate

mDSD

modified Daily Symptom Diary

PFS

Progression Free Survival

TRAE

Treatment Related Adverse Events

CRC

Colorectal Cancer

Mel

Melanoma

POC

Proof of Concept

TE

Transplant Eligible

DFS

Disease-free survival

MF

Myelofibrosis

PsA

Psoriatic Arthritis

TNF

Tumor Necrosis Factor

DLBCL

Diffuse Large B-Cell Lymphoma

MIUC

Muscle Invasive Urothelial Cancer

PsO

PsoriasisUC

Ulcerative Colitis

DLE

Discoid Lupus Erythematosus

MM

Multiple Myeloma

QD

Once Daily

VO2

Volume of Oxygen

DLT

Dose Limiting Toxicity
European Academy of Dermatology
and Venereology

MR

Minimal Response

QW

Once WeeklyMS

Multiple Sclerosis

RBC-TI Red Blood Cell Transfusion Independence

EASI

Eczema Area & Severity Index

MSI-H

High Microsatellite Instability

RCC

Renal Cell Carcinoma

EFS

Event Free Survival

MSS

Microsatellite Stable

RFS

Recurrence-free survival

RP2D

Recommended Phase 2 DoseEADV

Q3 2023 Results

56
Not for Product Promotional Use